FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149862420> ?p ?o ?g. }

• W2149862420 endingPage "413" @default.
• W2149862420 startingPage "405" @default.
• W2149862420 abstract "<h2>Summary</h2><h3>Background</h3> Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT_1F receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral lasmiditan for the acute treatment of migraine. <h3>Methods</h3> In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg lasmiditan, or placebo. Study drug and placebo were supplied in identical numbered tablet packs. The randomisation code was generated by an independent statistician. Patients and investigators were masked to treatment allocation. The primary endpoint was dose response for headache relief (moderate or severe becoming mild or none) at 2 h. The primary analysis was done in the modified intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00883051. <h3>Findings</h3> Between July 8 2009, and Feb 18, 2010, 512 patients were randomly assigned to treatment, 391 of whom received treatment. 86 patients received placebo (81 included in primary analysis) and 305 received lasmiditan (50 mg n=79, 100 mg n=81, 200 mg n=69, and 400 mg n=68 included in primary analysis). There was a linear association between headache response rate at 2 h and lasmiditan dose (Cochran-Armitage test p<0·0001). Every lasmiditan treatment dose significantly improved headache response at 2 h compared with placebo (lasmiditan 50 mg: difference 17·9%, 95% CI 3·9–32·1, p=0·022; 100 mg: 38·2%, 24·1–52·4, p<0·0001; 200 mg: 28·8%, 9·6–39·9, p=0·0018; 400 mg: 38·7%, 23·9–53·6, p<0·0001). The proportion of patients with treatment-emergent adverse events increased with increasing doses (53/82 [65%], 59/82 [72%], 61/71 [86%], and 59/70 [84%] for lasmiditan 50, 100, 200, and 400 mg, respectively <i>vs</i> 19/86 [22%] for placebo). Most adverse events were mild or moderate in intensity, with 16 of 82 (20%), 23 of 82 (28%), 28 of 71 (39%), and 31 of 70 (44%) of patients on lasmiditan 50, 100, 200, and 400 mg, respectively reporting a severe adverse event compared with five of 86 (6%) on placebo. The most common adverse events were CNS related and included dizziness, fatigue, vertigo, paraesthesia, and somnolence. <h3>Interpretation</h3> Oral lasmiditan seems to be safe and effective in the acute treatment of migraine. Further assessment in larger placebo-controlled and triptan-controlled trials are needed to assess the potential role of lasmiditan in acute migraine therapy. <h3>Funding</h3> CoLucid Pharmaceuticals." @default.
• W2149862420 created "2016-06-24" @default.
• W2149862420 creator A5000925048 @default.
• W2149862420 creator A5011781188 @default.
• W2149862420 creator A5017428431 @default.
• W2149862420 creator A5018653939 @default.
• W2149862420 creator A5033104412 @default.
• W2149862420 creator A5051082265 @default.
• W2149862420 creator A5060391100 @default.
• W2149862420 creator A5084347609 @default.
• W2149862420 date "2012-05-01" @default.
• W2149862420 modified "2023-10-16" @default.
• W2149862420 title "Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study" @default.
• W2149862420 cites W1975188327 @default.
• W2149862420 cites W1977551632 @default.
• W2149862420 cites W1983283512 @default.
• W2149862420 cites W1989219441 @default.
• W2149862420 cites W1993133868 @default.
• W2149862420 cites W2010242820 @default.
• W2149862420 cites W2022575186 @default.
• W2149862420 cites W2036354453 @default.
• W2149862420 cites W2037610022 @default.
• W2149862420 cites W2038290582 @default.
• W2149862420 cites W2047700866 @default.
• W2149862420 cites W2049691147 @default.
• W2149862420 cites W2055830009 @default.
• W2149862420 cites W2110701887 @default.
• W2149862420 cites W2125197474 @default.
• W2149862420 cites W2125664611 @default.
• W2149862420 cites W2135858080 @default.
• W2149862420 doi "https://doi.org/10.1016/s1474-4422(12)70047-9" @default.
• W2149862420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22459549" @default.
• W2149862420 hasPublicationYear "2012" @default.
• W2149862420 type Work @default.
• W2149862420 sameAs 2149862420 @default.
• W2149862420 citedByCount "147" @default.
• W2149862420 countsByYear W21498624202012 @default.
• W2149862420 countsByYear W21498624202013 @default.
• W2149862420 countsByYear W21498624202014 @default.
• W2149862420 countsByYear W21498624202015 @default.
• W2149862420 countsByYear W21498624202016 @default.
• W2149862420 countsByYear W21498624202017 @default.
• W2149862420 countsByYear W21498624202018 @default.
• W2149862420 countsByYear W21498624202019 @default.
• W2149862420 countsByYear W21498624202020 @default.
• W2149862420 countsByYear W21498624202021 @default.
• W2149862420 countsByYear W21498624202022 @default.
• W2149862420 countsByYear W21498624202023 @default.
• W2149862420 crossrefType "journal-article" @default.
• W2149862420 hasAuthorship W2149862420A5000925048 @default.
• W2149862420 hasAuthorship W2149862420A5011781188 @default.
• W2149862420 hasAuthorship W2149862420A5017428431 @default.
• W2149862420 hasAuthorship W2149862420A5018653939 @default.
• W2149862420 hasAuthorship W2149862420A5033104412 @default.
• W2149862420 hasAuthorship W2149862420A5051082265 @default.
• W2149862420 hasAuthorship W2149862420A5060391100 @default.
• W2149862420 hasAuthorship W2149862420A5084347609 @default.
• W2149862420 hasConcept C126322002 @default.
• W2149862420 hasConcept C142724271 @default.
• W2149862420 hasConcept C168563851 @default.
• W2149862420 hasConcept C170493617 @default.
• W2149862420 hasConcept C197934379 @default.
• W2149862420 hasConcept C203092338 @default.
• W2149862420 hasConcept C204787440 @default.
• W2149862420 hasConcept C27081682 @default.
• W2149862420 hasConcept C2776312127 @default.
• W2149862420 hasConcept C2777350023 @default.
• W2149862420 hasConcept C2778375690 @default.
• W2149862420 hasConcept C2778541695 @default.
• W2149862420 hasConcept C2778871607 @default.
• W2149862420 hasConcept C2778938600 @default.
• W2149862420 hasConcept C2991744798 @default.
• W2149862420 hasConcept C42219234 @default.
• W2149862420 hasConcept C71924100 @default.
• W2149862420 hasConceptScore W2149862420C126322002 @default.
• W2149862420 hasConceptScore W2149862420C142724271 @default.
• W2149862420 hasConceptScore W2149862420C168563851 @default.
• W2149862420 hasConceptScore W2149862420C170493617 @default.
• W2149862420 hasConceptScore W2149862420C197934379 @default.
• W2149862420 hasConceptScore W2149862420C203092338 @default.
• W2149862420 hasConceptScore W2149862420C204787440 @default.
• W2149862420 hasConceptScore W2149862420C27081682 @default.
• W2149862420 hasConceptScore W2149862420C2776312127 @default.
• W2149862420 hasConceptScore W2149862420C2777350023 @default.
• W2149862420 hasConceptScore W2149862420C2778375690 @default.
• W2149862420 hasConceptScore W2149862420C2778541695 @default.
• W2149862420 hasConceptScore W2149862420C2778871607 @default.
• W2149862420 hasConceptScore W2149862420C2778938600 @default.
• W2149862420 hasConceptScore W2149862420C2991744798 @default.
• W2149862420 hasConceptScore W2149862420C42219234 @default.
• W2149862420 hasConceptScore W2149862420C71924100 @default.
• W2149862420 hasIssue "5" @default.
• W2149862420 hasLocation W21498624201 @default.
• W2149862420 hasLocation W21498624202 @default.
• W2149862420 hasOpenAccess W2149862420 @default.
• W2149862420 hasPrimaryLocation W21498624201 @default.
• W2149862420 hasRelatedWork W1982089628 @default.
• W2149862420 hasRelatedWork W1986907391 @default.

• next